3mlv
From Proteopedia
(Difference between revisions)
| Line 6: | Line 6: | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3mlv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3mlv OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3mlv RCSB], [http://www.ebi.ac.uk/pdbsum/3mlv PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3mlv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3mlv OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3mlv RCSB], [http://www.ebi.ac.uk/pdbsum/3mlv PDBsum]</span></td></tr> | ||
</table> | </table> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/Q79790_9HIV1 Q79790_9HIV1]] The envelope glyprotein gp160 precursor down-modulates cell surface CD4 antigen by interacting with it in the endoplasmic reticulum and blocking its transport to the cell surface.[SAAS:SAAS00139820] The gp120-gp41 heterodimer allows rapid transcytosis of the virus through CD4 negative cells such as simple epithelial monolayers of the intestinal, rectal and endocervical epithelial barriers. Both gp120 and gp41 specifically recognize glycosphingolipids galactosyl-ceramide (GalCer) or 3' sulfo-galactosyl-ceramide (GalS) present in the lipid rafts structures of epithelial cells. Binding to these alternative receptors allows the rapid transcytosis of the virus through the epithelial cells. This transcytotic vesicle-mediated transport of virions from the apical side to the basolateral side of the epithelial cells does not involve infection of the cells themselves.[SAAS:SAAS00140087] | ||
== Evolutionary Conservation == | == Evolutionary Conservation == | ||
[[Image:Consurf_key_small.gif|200px|right]] | [[Image:Consurf_key_small.gif|200px|right]] | ||
Revision as of 04:18, 25 December 2014
Crystal structure of anti-HIV-1 V3 Fab 2557 in complex with an NOF V3 peptide
| |||||||||||
